Black Box Warning

The FDA Warning Hierarchy

Warning Levels

Level	Severity	Location on Label
Black Box Warning	Most serious	Top of label in bordered box
Warnings and Precautions	Serious	Label body
Adverse Reactions	All reported events	Label body
Drug Interactions	Interaction risks	Label body

What Triggers a Black Box

FDA adds a black box warning when there is:

• Serious or life-threatening adverse reaction risk
• Important contraindication requiring emphasis
• Special monitoring or restricted use requirements
• Risk of severe reactions in specific populations
• Safety issue requiring careful benefit-risk consideration

Anatomy of a Black Box Warning

Standard Elements

Component	Purpose
Black border	Visual prominence
WARNING header	Immediate attention
Specific risk	What can happen
Affected populations	Who is at risk
Recommended actions	What to do about it
Contraindications	When to never use

Example Format

WARNING: RISK OF [CONDITION]
[Drug class] cause [adverse effect] in [study type].
It is unknown whether [drug] causes [condition] in humans.
[Drug] is contraindicated in patients with [risk factors].

GLP-1 Agonist Black Box Warning

The Warning Text

All GLP-1 receptor agonists carry this warning:

WARNING: RISK OF THYROID C-CELL TUMORS

In rodents, [drug name] causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether [drug name] causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance of [drug name]-induced rodent thyroid C-cell tumors has not been determined.

[Drug name] is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

What This Means in Practice

Finding	Interpretation
Rodent tumors	Observed in animal studies at various doses
Human relevance	Unknown - humans have far fewer C-cell GLP-1 receptors
Contraindications	Personal/family MTC history, MEN 2 syndrome
Monitoring	Report thyroid symptoms to healthcare provider

Affected Medications

Generic Name	Brand Names	Warning
Semaglutide	Ozempic, Wegovy, Rybelsus	Yes - Thyroid C-cell
Tirzepatide	Mounjaro, Zepbound	Yes - Thyroid C-cell
Liraglutide	Victoza, Saxenda	Yes - Thyroid C-cell
Dulaglutide	Trulicity	Yes - Thyroid C-cell
Exenatide	Byetta, Bydureon	Yes - Thyroid C-cell

Context for the GLP-1 Warning

Why It Exists

Factor	Explanation
Regulatory requirement	Animal findings require disclosure
Precautionary principle	Unknown human risk warrants caution
Class-wide	All GLP-1 agents show similar animal findings
Consistency	Same warning enables consistent patient communication

Current Evidence

Evidence Type	Finding
Animal studies	Tumors at high doses, long duration
Human clinical trials	No signal detected
Post-marketing surveillance	No increased MTC rates identified
Epidemiological studies	No association found to date
Biological plausibility	Humans have fewer C-cell GLP-1 receptors

Why Human Risk May Be Lower

• Rodents have many more thyroid C-cell GLP-1 receptors than humans
• Human C-cells respond differently to GLP-1
• Millions of patient-years of exposure without signal
• MTC is extremely rare (1-2 per million), making detection difficult

Clinical Implications

Before Prescribing

Step	Purpose
Family history screening	Identify MTC in blood relatives
Personal history review	Identify prior thyroid cancer
MEN 2 assessment	Screen for syndrome
Patient education	Explain warning and symptoms

During Treatment

Monitoring	Recommendation
Thyroid symptoms	Educate patient on what to report
Neck examination	Per routine medical care
Thyroid function tests	Not specifically required for monitoring
Calcitonin measurement	Not recommended for routine screening

Patient Counseling Points

• Explain the animal study findings
• Clarify unknown human relevance
• Review contraindications
• Describe symptoms to report: neck lump, hoarseness, difficulty swallowing
• Emphasize overall benefit-risk assessment

Other Drugs with Black Box Warnings

Common Black Box Categories

Category	Examples
Cardiovascular risk	NSAIDs, certain diabetes drugs
Suicidality	Antidepressants (in youth)
Infection risk	Immunosuppressants
Bleeding risk	Anticoagulants
Hepatotoxicity	Various medications
Addiction potential	Opioids, benzodiazepines

Perspective

Black box warnings do not mean a drug is unsafe for appropriate patients. They ensure informed prescribing decisions by highlighting serious risks that must be weighed against benefits.

Frequently Asked Questions

Should I be worried about thyroid cancer from GLP-1 agonists?

Based on current evidence, human risk appears very low. The warning exists because animal studies showed tumors, and FDA requires disclosure of potential risks. Millions of patients have used these medications without increased thyroid cancer rates. Discuss your specific risk factors with your healthcare provider.

Can I take GLP-1 agonists if I have thyroid problems?

Most thyroid conditions are NOT contraindications. Only personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are absolute contraindications. Hypothyroidism, Hashimoto’s, Graves’ disease, and most thyroid nodules are not contraindications.

What symptoms should I report while taking GLP-1 agonists?

Report: lump or swelling in neck, hoarseness or voice changes, difficulty swallowing, shortness of breath. These could indicate thyroid issues requiring evaluation, though they have many causes.

Does the black box warning mean the drug is dangerous?

It means there’s a serious risk that requires awareness, not that the drug is inherently dangerous for appropriate patients. Many effective, commonly used medications have black box warnings. The key is ensuring the warning applies to your situation and that benefits outweigh risks.